SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
Brain Metastases
DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: ProHance
Number of Lesions Detected by Blinded Readers (BR) and Investigator, Number of metastatic lesions (unenhanced and enhanced) per participant detected on postcontrast Magnetic resonance (MR) images by averaged blinded reader and investigator, one day
Score of Visibility Assessment - Degree of Lesion Contrast Enhancement by Blinded Reader, Degree of contrast enhancement for each lesion on postcontrast MR images using the 4-point scale by averaged blinded reader (Score 1=No, 2=Moderate, 3=Good, 4=Excellent), one day|Score of Visibility Assessment - Degree of Lesion Contrast Enhancement by Investigator, Degree of contrast enhancement for each lesion on postcontrast MR images using the 4-point scale by investigator (Score 1=No, 2=Moderate, 3=Good, 4=Excellent), one day|Score of Visibility Assessment - Border Delineation by Blinded Reader, Border delineation for each lesion on postcontrast MR images using the 4-point scale by averaged blinded reader (Score 1=None, 2=Moderate, 3=Good, 4=Excellent), one day|Score of Visibility Assessment - Border Delineation by Investigator, Border delineation for each lesion on postcontrast MR images using the 4-point scale by investigator (Score 1=None, 2=Moderate, 3=Good, 4=Excellent), one day|Treatment Planning Confidence - Gadobutrol 0.1 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Treatment Planning Experts (TPE), Treatment planning confidence evaluated separately for each image set (gadobutrol \[Gado-\] 0.1 mmol/kg bw and gadoteridol \[Pro-\] 0.2 mmol/kg) by TPE (category: not confident, confident, and not assessable), one day|Treatment Planning Confidence - Gadobutrol 0.1 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Investigator, Treatment planning confidence evaluated separately for each image set (gadobutrol 0.1 mmol/kg bw and gadoteridol 0.2 mmol/kg) by investigator (category: not confident, confident, and not assessable), one day|Treatment Planning Confidence - Gadobutrol 0.2 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by TPE, Treatment planning confidence evaluated separately for each image set (gadobutrol 0.2 mmol/kg bw and gadoteridol 0.2 mmol/kg) by TPE (category: not confident, confident, and not assessable), one day|Treatment Planning Confidence - Gadobutrol 0.2 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Investigator, Treatment planning confidence evaluated separately for each image set (gadobutrol 0.2 mmol/kg bw and gadoteridol 0.2 mmol/kg) by investigator (category: not confident, confident, and not assessable), one day|Number of Participants With Performance in Stereotactic Radiosurgery (SRS) Planning by TPE, Comparison of overall image quality for SRS treatment planning between gadobutrol and gadoteridol by TPE, one day|Number of Participants With Performance in Stereotactic Radiosurgery (SRS) Planning by Investigator, Comparison of overall image quality for SRS treatment planning between gadobutrol and gadoteridol by investigator, one day|Number of Participants With Reasons for Performance in SRS Planning by TPE, Reasons for comparison results of overall image quality for SRS treatment planning between gadobutrol and gadoteridol by investigator (multiple answers applicable), one day|Number of Participants With Reasons for Performance in SRS Planning by Investigator, Reasons for comparison results of overall image quality for SRS treatment planning between gadobutrol and gadoteridol by investigator (multiple answers applicable), one day|Lesion Size Evaluated by Independent Radiologist, Size of each lesion on postcontrast MR images evaluated by independent radiologist (mean and standard deviation of 603 lesions), one day|Contrast Noise Ratio (CNR) of Lesions Evaluated by Independent Radiologist, CNR of lesion/normal white matter based on the signal intensity of MR images evaluated by independent radiologist (mean and standard deviation of 306 lesions), one day|Intraclass Correlation Coefficient (ICC) Among 3 Blinded Readers on the Number of Detected Lesions, ICC among 3 blinded readers calculated for number of detected lesions using the statistical model with two random effects, i.e., blinded readers and individual patients., one day
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.